Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Intra-tumoral hypoxia is common in solid tumors.
• Hypoxia-inducible factor 1α (HIF1α) drives malignant progression.
• HIF1α stabilization is often mediated by heat shock protein 90 (HSP90).

Purpose of the Study:

• To investigate a dual inhibition strategy targeting HIF1α.
• To evaluate the combined inhibition of cyclin-dependent kinases (CDKs) and HSP90.
• To assess the therapeutic potential of this approach in various cancers.

Main Methods:

• Dual inhibition of CDK1 and HSP90.
• Utilizing FDA-approved CDK4/6 inhibitors with HSP90 inhibition.
• Assessing apoptosis, cancer cell viability, and tumor growth in vitro and in vivo.

Main Results:

• CDK1 knockdown enhanced HSP90 inhibition's effect on HIF1α.
• Dual CDK1/HSP90 inhibition increased apoptosis and reduced cancer cell viability.
• Combined CDK4/6 and HSP90 inhibition demonstrated a class effect across multiple cancer types, suppressing tumor growth in vivo.

Conclusions:

• Combined targeting of CDKs (CDK1 or CDK4/6) and HSP90 effectively inhibits HIF1α expression.
• This dual inhibition strategy exhibits promising anti-cancer efficacy and therapeutic potential.